Transcutaneous immunization and immunostimulant strategies: Capitalizing on the immunocompetence of the skin

Expert Review of Vaccines

Volumn 2, Issue 2, 2003, Pages 253-267

  Glenn, Gregory M ^a   Kenney, Richard T ^a   Ellingsworth, Larry R ^a   Frech, Sarah A ^a   Hammond, Scott A ^a   Zoeteweij, J Paul ^a  

^a IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; ALUMINUM HYDROXIDE; ANTIGEN; BACTERIAL DNA; BACTERIAL TOXIN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CS6 ANTIGEN; CYTOKINE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; EXOTOXIN; GLYCEROL; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOPOLYSACCHARIDE; M PROTEIN; NICOTINE; OVALBUMIN; PARACETAMOL; PNEUMOCOCCUS VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; TETANUS TOXOID; TRIPLE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; HYDRATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INJECTION; KERATINOCYTE; LANGERHANS CELL; MUCOSAL IMMUNITY; NONHUMAN; PAPER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN PENETRATION; SKIN STRUCTURE; STRATUM CORNEUM; STREPTOCOCCUS INFECTION; TETANUS; TOPICAL TREATMENT; TRANSDERMAL PATCH;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; GUINEA PIGS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOCOMPETENCE; LANGERHANS CELLS; MICE; SKIN; VACCINES;

EID: 0037992570     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.2.253     Document Type: Review

References (59)

1. Glenn GM, Kenney RT. Transcutaneous immunization. In: New Generation Vaccines. Levine MM, Kaper JB, Rappuoli R, Liu M, Good M (Eds.). Marcel Dekker, Inc., NY, USA (In Press).
2. Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv. Dermatol. 14, 209-258 (1999).
3. Yu RC, Abrams DC, Alaibac M, Chu AC. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br. J. Dermatol. 131(6), 843-848 (1994).
4. Udey MC. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol. 107(Suppl. 1), 6-8 (1997).
5. Guereña-Burgueño F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70(4), 1874-1880 (2002).
6. Roberts MS, Walker M. Water, the most natural penetration enhancer. Marcel Dekker, NY, USA, 1-30 (1993).
7. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skinbarrier function and targeted epidermal delivery. Nat. Med. 8(4), 415-419 (2002).
8. Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 19(20-22), 2908-2917 (2001).
9. Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipidbased biphasic delivery system. Vaccine 18(17), 1847-1854 (2000).
10. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 391 (6670), 851 (1998).
11. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits and unrelated adjuvants. Infect. Immun. 68(9), 5306-5313 (2000).
12. O'Hagan DT (Ed.). Methods in Molecular Medicine. Humana Press, Inc., NJ, USA (2000).
13. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63(5), 1617-1623 (1995).
14. Freyrag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236, 215-236 (1999).
15. Gluck R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heatlabile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 11129-1132 (2000).
16. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heatl-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116(4), 804-812 (1999).
17. Snider DE. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15(3-4), 317-348 (1995).
18. Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heatlabile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun. 68(5), 2775-2782 (2000).
19. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine 19, 2701-2707 (2001).
20. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide- specific CTLs and protection against tumor development in vivo. J. Immunol. 158(2), 834-841 (1997).
21. Neidleman JA, Ott G, O'Hagan D. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O'Hagan D (Ed.). Humana Press, NJ, USA, 327-336 (2000).
22. Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl Acad. Sci. USA 97(1), 371-376 (2000).
23. Levine MM, Kaper JB, Black RE, Clements ML New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47(4), 510-550 (1983).
24. Murphy GF, Messadi D, Fonferko E, Hancock WW. Phenotypic transformation of macrophages to Langerhans cells in the skin. Am. J. Pathol. 123(3), 401-406 (1986).
25. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12), 1403-1406 (2000).
26. El-Ghorr AA, Williams RM, Heap C, Norval M. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol. Med. Microbiol. 29(4), 255-261 (2000).
27. Gockel CM, Bao S, Beagley KW. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37(9), 537-544 (2000).
28. Jakob T, Walker PS, Krieg AM, von Stebut E, Udey MC, Vogel JC. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int. Arch. Allergy Immunol. 118(2-4), 457-461 (1999).
29. Kremer IB, Stevens SR, Gould JW, DiCarlo J, Quinby GE, Cooper KD. Intradermal granulocyte-macrophage colony-stimulating factor alters cutaneous antigen-presenting cells and differentially affects local versus distant immunization in humans. Clin. Immunol. 96(1), 29-37 (2000).
30. Alba S, Katz SI. Phenotypic and functional characteristics of in vivoactivated Langerhans cells. J. Immunol. 145(9), 2791-2796 (1990).
31. Hernando RA, Ruby JC, Halliday GM. Changes in epidermal Langerhans cells, γδ T-cells and CD4 T-cells after intradermal infection with recombinant vaccinia virus expressing cytokine genes. Immunol. Cell Biol. 72(5), 383-389 (1994).
32. Nagao S, Inaba S, Iijima S. Langerhans cells at the sites of vaccinia virus inoculation. Arch. Dermatol. Res. 256(1), 23-31 (1976).
33. Vassell R, Glenn GM, Udey MC, Scharron-Kersten T, Alving CR, Jakob T. In: 5th National Symposium, Basic Aspects of Vaccines. MD, USA (1999).
34. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J. Virol. (In Press).
35. Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit. Rev. Ther. Drug Carrier Sys. 18 (5), 503-526 (2001).
36. Arrington J, Braun RP, Dong L et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol. 76(9), 4536-4546 (2002).
37. Kripke ML, Munn CG, Jeevan A, Tang JM, Bucana C. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145(9), 2833-2838 (1990).
38. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18(24), 2753-2767 (2000).
39. Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17(2), 135-140 (2001).
40. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17(11), 1075-1081 (1999).
41. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767-811 (2000).
42. Morein B, Lovgren-Bengtsson K, Cox J. Modern adjuvants, functional aspects. In: Concepts in Vaccine Development. Kaufmann SHE (Ed.) Walter de Gruyter, Berlin, Germany, 243-263 (1996).
43. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388(6644), 782-787 (1997).
44. Rescigno M, Citterio S, Thery C et al. Bacteria-induced neo-biosynthesis, stabilization and surface expression of functional class I molecules in mouse dendritic cells. Proc. Natl Acad. Sci. USA 95(9), 5229-5234 (1998).
45. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis. 179(1), 31-36 (1999).
46. Hammond SA, Tsonis C, Sellins K et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv. Drug Delivery Rev. 43, 45-55 (2000).
47. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67(3), 1100-1106 (1999).
48. Kodoff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacterpylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69(6), 3581-3590 (2001).
49. Watabe S, Xin K, Ihata A et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19(31), 4434-4444 (2001).
50. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. Immunol. 161(7), 3211-3214 (1998).
51. Gebhart W, Metze D, Jurecka W. IgA in human skin appendages. In: Immunodermatology. Caputo R (Ed.). CIC Edizioni Internazionali, Rome, Italy, 185 (1987).
52. Okada T, Konishi H, Ito M, Nagura H, Asai J. Identification of secretory immunoglobulin A in human sweat and sweat glands. J. Invest. Dermatol. 90(5), 648-651 (1988).
53. Hard GC. Electron microscopic examination of Corynebacterium ovis. J. Bacteriol. 97(3), 1480-1485 (1969).
54. Metze D, Kersten A, Jurecka W, Gebhart W. Immunoglobulins coat microorganisms of skin surface: a comparative immunohistochemical and ultrastructural study of cutaneous and oral microbial symbionts. J. Invest. Dermatol. 96(4), 439-445 (1991).
55. Yu J, Cassels F, Scharton-Kersten T et al. Transcutaneous immunization using colonization factor and heat labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70(3), 1056-1068 (2002).
56. Wolf MK, de Haan LA, Cassels FJ et al. The CS6 colonization factor of human enterotoxigenic Escherichia coli contains two heterologous major subunits. FEMS Microbiol. Lett. 148(1), 35-42 (1997).
57. Levine MM, Ristaino P, Sack RB, Kaper JB, Orskov F, Orskov I. Colonization factor antigens I and II and Type 1 somatic pili in enterotoxigenic Escherichia coli: relation to enterotoxin type. Infect. Immun. 39(2), 889-897 (1983).
58. Wolf M, Hall E, Taylor D et al. In: The 35th Joint Conference of the US-Japan Co-operative Medical Science Program. Baltimore, MD, USA (1999).
59. Trach DD, Clemens JD, Ke NT et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349(9047), 231-235 (1997).